MedPath

Insulin-based Strategies to Prevent Hypoglycemia During Two Types of Exercise

Not Applicable
Completed
Conditions
Type 1 Diabetes Mellitus
Interventions
Other: Continous exercise
Other: Interval exercise
Other: Reduction of basal insulin by 40%
Other: Reduction of basal insulin by 80%
Registration Number
NCT03845114
Lead Sponsor
Institut de Recherches Cliniques de Montreal
Brief Summary

Regular exercise is associated with many health benefits for individuals with type 1 diabetes. However, immediate and delayed exercise-induced hypoglycemia is frequent and thus the main limiting factor for physical activity practice in this population. To reduce the risk of exercise-induced hypoglycemia, two types of adjustments may be considered by patients with type 1 diabetes : pre-meal insulin-dose reduction and carbohydrate supplements. Few evidence-based recommendations are available for patients using insulin pump to adjust insulin doses in order to limit exercise-induced hypoglycemia. The objective of this study is to address the magnitude of the needed reduction during two types of frequently practiced exercise (continuous vs. interval exercise) known to have a different impact on blood glucose reduction.

Detailed Description

Each study participant will be admitted at IRCM one to five days after sensor insertion. Participants will be asked to change their pump catheter 24 to 36 hours prior to the intervention visit. On the day of the intervention visit, participants will have a standardized lunch (45-65g CHO for females and 60-80g CHO for males ) at 12:00 and will be asked not to eat afterwards (except for correction of hypoglycemia). Participants will be asked not to exercise (excluding light exercise such as walking or taking the stairs) the day before and the day of the intervention visit. Participants will be asked not to consume caffeine after 12:00 the day of the intervention. The day before the intervention and the day of the intervention, participants will be asked to refrain from alcohol consumption. Participants will be blinded to the strategy used during the exercise intervention. Participants will be admitted at IRCM at 14:00. A catheter will be installed for plasma glucose and insulin measurements. At 14:30, insulin basal rate will be reduced by 40% or 80% depending of randomization. At 15:30, participants will undertake a continuous exercise (60-minute exercise on the ergocycle at 60% of VO2 peak) or an interval exercise (2-minutes alternating intervals at 85% and 50% of VO2peak for 50-minutes, with 5-minutes at 45% VO2peak at the start and the end of exercise). As a safety measure, plasma glucose will be measured every 10 minutes. Participants will be blinded to sensor glucose levels as well as plasma glucose measurements. At 17:00, the participant will be discharged if glucose levels are above 5.5 mmol/L. Participants will be asked to eat a standardized dinner at home (45-65g CHO for females and 60-80g CHO for males). Participants will have the freedom to choose at what time they wish to have dinner but it will have to be similar on all intervention visits.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
37
Inclusion Criteria
  1. Males and females ≥ 14 years of old.
  2. Clinical diagnosis of type 1 diabetes for at least two years.
  3. The subject will have been on insulin pump therapy for at least 3 months.
  4. Last (less than 2 months) HbA1c ≤ 10%.
Exclusion Criteria
  1. Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy or severe proliferative retinopathy as judged by the investigator.
  2. Recent (< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.
  3. Abnormal blood panel and/or anemia.
  4. Ongoing pregnancy.
  5. Severe hypoglycemic episode within two weeks of screening.
  6. Other serious medical illness likely to interfere with study participation or with the ability to complete the exercise periods by the judgment of the investigator (e.g. orthopedic limitation).
  7. Failure to comply with team's recommendations (e.g. not willing to change pump parameters, etc.).

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Continuous exercise - Basal insulin reduced by 40%Continous exercise-
Continuous exercise - Basal insulin reduced by 40%Reduction of basal insulin by 40%-
Interval exercise - Basal insulin reduced by 40%Interval exercise-
Continuous exercise - Basal insulin reduced by 80%Continous exercise-
Interval exercise - Basal insulin reduced by 40%Reduction of basal insulin by 40%-
Interval exercise - Basal insulin reduced by 80%Interval exercise-
Interval exercise - Basal insulin reduced by 80%Reduction of basal insulin by 80%-
Continuous exercise - Basal insulin reduced by 80%Reduction of basal insulin by 80%-
Primary Outcome Measures
NameTimeMethod
Decrease in plasma glucose levels during exercise60 minutes

Difference between glucose levels at the beginning of the exercise and the lowest glucose levels from the start of the exercise until the end of exercise

Secondary Outcome Measures
NameTimeMethod
Number of patients with an exercise-induced hypoglycemia < 3.5 mmol/L60 minutes
Percentage of time of plasma glucose levels spent > 10 mmol/L60 minutes
Percentage of time of plasma glucose levels spent between 4-10 mmol/L60 minutes
Amount of carbohydrates needed to treat a hypoglycemic event60 minutes
Decremental area under the curve of plasma glucose levels60 minutes
Area under the curve of plasma glucose levels < 4 mmol/L60 minutes
Mean time to the first hypoglycemic event60 minutes
Number of patients with an exercise-induced hypoglycemia < 3.9 mmol/L60 minutes
Total number of hypoglycemia episodes requiring treatment60 minutes
Percentage of time of plasma glucose levels spent below 4 mmol/L60 minutes
Number of patients requiring an oral treatment for hypoglycemia60 minutes

Trial Locations

Locations (2)

Institut de recherches cliniques de Montréal

🇨🇦

Montreal, Quebec, Canada

McGill University Health Center

🇨🇦

Montreal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath